Management of Canadian patients with refractory or relapsed diffuse large B-cell lymphoma in the real world: a subanalysis of the RE-MIND2 study
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf330 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift The Oncologist, 2025. Verfasst von Anthea Peters und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Neoplasm Recurrence, Local, Immunotherapy, Adoptive. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Incyte Corporation.
Abstract (Originalsprache)
Background
In the current Canadian treatment landscape for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL), eligibility for autologous stem cell transplantation (ASCT) guides the choice of salvage treatment. CD19 chimeric antigen receptor T-cell (CAR-T) therapies have improved outcomes in patients with chemorefractory DLBCL, but access is limited to eligible patients. This subanalysis of the RE-MIND2 observational retrospective cohort study investigated treatment patterns for R/R DLBCL in Canada. Patients and methods Data from patients enrolled in RE-MIND2 treated between 2010 and 2020 at 2 Canadian centers were retrospectively collected from health records. Descriptive statistics were used to analyze baseline characteristics, treatment initiated, and duration of treatment by line of therapy.
Results
One hundred and nine patients were included; 74.2% of patients were eligible for ASCT as 2L therapy, and 45.4% received transplants. ASCT eligibility for third- (3L) and fourth-line (4L) therapy declined to 17.1% and 5.9%, respectively. Patients received a wide variety of treatments in 3 and 4L. CAR-T therapy became available in 3 and 4L by the end of 2019. Median durations of treatment were <2.6 months in all lines of therapy; median time to next treatment ranged from 3.4 months in 4L to 5.3 months in 2L.
Conclusion
Results of our study support that ASCT-ineligible patients have a poor prognosis with conventional salvage chemotherapy. Before the availability of novel immunotherapies, no apparent standard of care was observed for Canadian patients with R/R DLBCL who were ineligible for or did not receive ASCT, especially after 2L treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada.
- Division of Hematology, Mayo Clinic, Rochester, MN 55905, United States.
- Medical Affairs - Hematology/Oncology, Incyte Biosciences Canada, Villle St Laurent, QC H4S 0A9, Canada.
- Global Epidemiology and RWE Statistics, Incyte Corporation, Wilmington, DE 19803, United States.
- Global Medical Affairs, MorphoSys AG, Planegg 82152, Germany.
- Hematology-Oncology and Cell Therapy University Institute, Hôpital Maisonneuve-Rosemont, Montreal University, Montreal, QC H1T 2M4, Canada.
ORCID-Profile: Anthea Peters
Förderung
- Incyte Corporation
Zitieren
APA
Peters, A., Nowakowski, G. S., Dabas, R., Amoloja, T., Xue, Z., Koch, C., Waltl, E. E., & Fleury, I. (2025). Management of Canadian patients with refractory or relapsed diffuse large B-cell lymphoma in the real world: a subanalysis of the RE-MIND2 study. The Oncologist. https://doi.org/10.1093/oncolo/oyaf330
Vancouver
Peters A, Nowakowski GS, Dabas R, Amoloja T, Xue Z, Koch C, et al. Management of Canadian patients with refractory or relapsed diffuse large B-cell lymphoma in the real world: a subanalysis of the RE-MIND2 study. The Oncologist. 2025. doi:10.1093/oncolo/oyaf330
BibTeX
@article{Peters2025,
author = {Peters, Anthea and Nowakowski, Grzegorz S and Dabas, Rosy and Amoloja, Theresa and Xue, Zhenyi and Koch, Caroline and Waltl, Eva E and Fleury, Isabelle},
title = {Management of Canadian patients with refractory or relapsed diffuse large B-cell lymphoma in the real world: a subanalysis of the RE-MIND2 study},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf330}
}
EUVIMED